Further Decision Processed by IB
05/28/2026
Back to search
Official data from USPTO
YMAGUS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
05/29/2026
Trademark type
Word
Nice classes
5
Filing date
11/29/2017
Registration date
05/08/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/22/2024
Last transaction
05/29/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
25
Owner location
CH
Examiner
MESSICK, TABITHA LEE
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Novartis AG
Representatives
Novartis Pharma AG, Trademark Department
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publications
History of USPTO decisions and trademark events.
18 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
04/28/2026
XXCR
GENERIC MADRID TRANSACTION CREATED
04/28/2026
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
07/22/2025
C71T
CANCELLED SECTION 71
11/22/2024
GPNX
NOTIFICATION PROCESSED BY IB
08/17/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/15/2018
FIMP
FINAL DISPOSITION PROCESSED
06/15/2018
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
06/07/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
05/08/2018
PUBO
PUBLISHED FOR OPPOSITION
02/20/2018
NPUB
NOTICE OF PUBLICATION
01/31/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/05/2018
DOCK
ASSIGNED TO EXAMINER
01/03/2018
MAFR
APPLICATION FILING RECEIPT MAILED
12/30/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/26/2017
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
12/22/2017
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
12/21/2017
Continuous trademark protection
Get notified about every new filing that threatens YMAGUS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.